Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Net Cash Flow (2016 - 2025)

Mimedx's Net Cash Flow history spans 15 years, with the latest figure at $24.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 53.94% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $61.7 million, up 175.27%, while the annual FY2025 figure was $61.7 million, 175.27% up from the prior year.
  • Net Cash Flow for Q4 2025 was $24.0 million at Mimedx, up from $23.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $24.0 million in Q4 2025 and bottomed at -$32.7 million in Q1 2024.
  • The 5-year median for Net Cash Flow is $1.4 million (2022), against an average of $3.9 million.
  • The largest annual shift saw Net Cash Flow crashed 1316.09% in 2022 before it soared 10441.06% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$3.5 million in 2021, then crashed by 106.21% to -$7.3 million in 2022, then skyrocketed by 97.92% to -$151000.0 in 2023, then skyrocketed by 10441.06% to $15.6 million in 2024, then skyrocketed by 53.94% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Net Cash Flow are $24.0 million (Q4 2025), $23.2 million (Q3 2025), and $12.4 million (Q2 2025).